Microbot Medical Inc (MBOT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$1.46-2.67%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Progress toward reducing losses and improving EPS: FY27 EPS -0.34 vs -0.32 target.
Microbot Medical is developing micro-robotic medical devices for less invasive surgeries. It has a strategic partnership with Emory University Hospital and a government vendor agreement to expand sales. The company aims to maintain its capital raising program to fund growth.
The company is loss-making with negative free cash flow and no clear path to profitability. Revenue estimates remain low, with EPS expected to stay negative through 2027. Capital raising efforts may face challenges given recent earnings misses.
The market reflects uncertainty with no consensus revenue growth or price targets available. Estimates show continued losses and modest revenue, indicating cautious expectations. Our view notes the high risk and unproven profitability.
Breaks if: ATM program is suspended or materially reduced
Continue to utilize the At The Market (ATM) offering program to raise capital as needed to support operations and growth.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risk, but it is focused on expanding its commercial adoption and manufacturing capabilities.
The market seems to have priced in a challenging environment, as MBOT's recent financial performance is below its industry peers. There is a medium level of confidence in the company's ability to execute its growth plans, but expectations are tempered by its current losses.
Management is on track with its priorities, particularly in expanding the LIBERTY System and establishing a second manufacturing site. However, the overall financial performance remains weak, and while recent momentum has improved, it is still fragile.
The thesis hinges on the performance of sector bellwethers like ABT, MDT, and SYK, which could influence MBOT's trajectory. Additionally, the company's ability to maintain its growth priorities and navigate potential recession fears will be crucial.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company reported an earnings beat, but revenue fell short of estimates. This raises concerns about its financial performance and outlook. The overall market has also shifted to a risk-off sentiment, which may impact MBOT negatively.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Newly stated in 2026-Q1. The company maintains an ATM program for capital raising as disclosed in 2026-Q1. No specific capital raise amounts or usage details are provided in the current data, so progress on this priority cannot be quantitatively assessed.
“Company previously entered into an ATM Offering Agreement with H.C. Wainwright & Co. for capital raising.”
Breaks if: EPS deteriorates beyond -$0.32 in FY27
Breaks if: revenue falls below $3.45M in FY26 or fails to grow toward $10.6M in FY27
In the next 1 to 3 years, MBOT's outlook will depend on its execution of growth strategies and broader healthcare sector trends. Not investment advice.